These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17604363)

  • 1. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.
    Buster EH; Hansen BE; Buti M; Delwaide J; Niederau C; Michielsen PP; Flisiak R; Zondervan PE; Schalm SW; Janssen HL;
    Hepatology; 2007 Aug; 46(2):388-94. PubMed ID: 17604363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [HBV genotype and liver histology effect of peginterferon alpha treatment of HBeAg-position chronic hepatitis B].
    Lu CT; Gao GS; Yan HD; Hu YR
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Jun; 27(3):193-5. PubMed ID: 24319954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
    Wong VW; Wong GL; Yan KK; Chim AM; Chan HY; Tse CH; Choi PC; Chan AW; Sung JJ; Chan HL
    Hepatology; 2010 Jun; 51(6):1945-53. PubMed ID: 20209602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.
    Buster EH; Flink HJ; Cakaloglu Y; Simon K; Trojan J; Tabak F; So TM; Feinman SV; Mach T; Akarca US; Schutten M; Tielemans W; van Vuuren AJ; Hansen BE; Janssen HL
    Gastroenterology; 2008 Aug; 135(2):459-67. PubMed ID: 18585385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.
    van Zonneveld M; Zondervan PE; Cakaloglu Y; Simon C; Akarca US; So TM; Flink HJ; de Man RA; Schalm SW; Janssen HL;
    Liver Int; 2006 May; 26(4):399-405. PubMed ID: 16629642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
    Marcellin P; Lau GK; Bonino F; Farci P; Hadziyannis S; Jin R; Lu ZM; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Button P; Pluck N;
    N Engl J Med; 2004 Sep; 351(12):1206-17. PubMed ID: 15371578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
    Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
    Dogan UB; Golge N; Akin MS
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on the relationship between hepatitis B virus genotypes and the effect of polyethylene glycol-interferon-alpha therapy on HBeAg-positive chronic hepatitis B].
    Gao GS; Xu XZ; Hu YR; Yan HD
    Zhonghua Nei Ke Za Zhi; 2013 Dec; 52(12):1009-12. PubMed ID: 24503396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.
    Bonino F; Marcellin P; Lau GK; Hadziyannis S; Jin R; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Brunetto MR; Farci P; Popescu M; McCloud P;
    Gut; 2007 May; 56(5):699-705. PubMed ID: 17127704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical effect and safety of pegylated interferon-α-2b injection (Y shape, 40 kD) in treatment of HBeAg-positive chronic hepatitis B patients].
    Hou FQ; Yin YL; Zeng LY; Shang J; Gong GZ; Pan C; Zhang MX; Yin CB; Xie Q; Peng YZ; Chen SJ; Mao Q; Chen YP; Mao QG; Zhang DZ; Han T; Wang MR; Zhao W; Liu JJ; Han Y; Zhao LF; Luo GH; Zhang JM; Peng J; Tan DM; Li ZW; Tang H; Wang H; Zhang YX; Li J; Zhang LL; Chen L; Jia JD; Chen CW; Zhen Z; Li BS; Niu JQ; Meng QH; Yuan H; Sun YT; Li SC; Sheng JF; Cheng J; Sun L; Wang GQ
    Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):589-596. PubMed ID: 29056008
    [No Abstract]   [Full Text] [Related]  

  • 13. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B.
    Zhu H; Wang C; Zhang Y; Wei S; Li X; Zhang Z
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1963-1970. PubMed ID: 27075693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo.
    Hansen BE; Rijckborst V; Ter Borg MJ; Janssen HL
    J Med Virol; 2011 Nov; 83(11):1917-23. PubMed ID: 21915866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
    Lu HY; Zhuang LW; Yu YY; Si CW; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
    Flink HJ; van Zonneveld M; Hansen BE; de Man RA; Schalm SW; Janssen HL;
    Am J Gastroenterol; 2006 Feb; 101(2):297-303. PubMed ID: 16454834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
    Janssen HL; van Zonneveld M; Senturk H; Zeuzem S; Akarca US; Cakaloglu Y; Simon C; So TM; Gerken G; de Man RA; Niesters HG; Zondervan P; Hansen B; Schalm SW; ;
    Lancet; 2005 Jan 8-14; 365(9454):123-9. PubMed ID: 15639293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Liver histopathological features influencing HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B responding to Peg-IFN treatment].
    Yan HD; Jiang FR; Zhu CL; Gao GS; Weng PJ; Hu AR; Xu CF; Hu YR; Sheng JF
    Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):340-4. PubMed ID: 24025133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine.
    Flink HJ; Hansen BE; Heathcote EJ; Feinman SV; Simsek H; Karayalcin S; Mach T; Leemans WF; de Man RA; Verhey E; Schalm SW; Janssen HL;
    Am J Gastroenterol; 2006 Nov; 101(11):2523-9. PubMed ID: 17029610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.